Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission.

Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2024

Tiso Francesca, Hebeda Konnie M, Langemeijer Saskia M C, de Graaf Aniek O, Martens Joost H A, Koorenhof-Scheele Thessa N, Knops Ruth, Kroeze Leonie I, van der Reijden Bert A, Jansen Joop H

Abstract excerpt

INTRODUCTION: Acute myeloid leukemia (AML) patients may receive hypomethylating agents such as decitabine (DAC) as part of their treatment. Not all patients respond to this therapy, and if they do, the clinical response may occur only after 3-6 courses of treatment. Hence, early biomarkers predicting response would be very useful. METHODS: We retrospectively analyzed a cohort of 22 AML patients who were treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Bone Marrow

Share to Decitabine

Share to DNA Methylation

Share to Leukemia, Myeloid, Acute

Share to Remission Induction

Source

Identifiers

PMID: 38643752
DOI: 10.1159/000538953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission.PMID 38643752Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.Semantic proximity Read ↗

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignanciesSemantic proximity Read ↗

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.Semantic proximity Read ↗

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experienceSemantic proximity Read ↗

Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMMLSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.